Cardiogenetic Centers
Definition
Interdisciplinary cardiogenetic centres are specialist clinical units that integrate cardiac electrophysiology, cardiac imaging, clinical genetics, genetic counselling, and an accredited genetic laboratory under one roof. Their purpose is directed diagnosis, risk assessment, therapy, and cascade family screening for single-gene cardiovascular diseases — particularly inherited arrhythmias and cardiomyopathies that are often unrecognized in general cardiology practice.
Key Concepts
Structure and Function
- A functional cardiogenetic centre requires experienced cardiologists (electrophysiology, imaging), pediatric cardiologists, clinical geneticists, and genetic counsellors — with laboratory accreditation for in-house variant classification. (sources/arrhythmia-genetics-mgenetik-2025 — high)
- Labs perform multi-gene panel (MGP) testing as standard; WES or WGS is used when targeted panels fail or when structural variants (SVs/CNVs) or non-coding variants are suspected. WGS is currently superior to WES for detecting SVs and regulatory variants. (sources/arrhythmia-genetics-mgenetik-2025 — high)
- Most current genetic tests in cardiogenetics are laboratory-developed tests (LDTs), validated and inspected by certified national organisations (EU requirement). (sources/arrhythmia-genetics-mgenetik-2025 — high)
- Currently concentrated at leading academic institutions; in Germany, structural and regulatory limitations restrict access; significant differences between private and public health insurance reimbursement. (sources/arrhythmia-genetics-mgenetik-2025 — high)
Goals of Molecular Genetic Testing in Probands
- Unravel the cause of cardiovascular disease and symptoms
- Provide a genetic diagnosis
- Provide prognostic information and adjust clinical management
- Identify disease-causing triggers (especially in inherited arrhythmia syndromes)
Role of Clinical Geneticists
- Responsible for informing patients and families about the implications of genetic results, including surveillance plans and family risk assessment. (sources/arrhythmia-genetics-mgenetik-2025 — high)
- Play a critical role in variant reinterpretation — integrating the cardiac phenotype in ways that diagnostic laboratories may not have the clinical expertise to do independently. (sources/arrhythmia-genetics-mgenetik-2025 — high)
- Any variant reclassification must be communicated to the requesting healthcare professional and to variant carriers. (sources/arrhythmia-genetics-mgenetik-2025 — high)
Variant Panel Strategy
- Larger multi-gene panels or WES do not substantially increase variant detection rate for confirmed diagnoses; they primarily increase ACMG class 3 (VUS) and secondary/incidental findings. (sources/arrhythmia-genetics-mgenetik-2025 — high)
- Targeted panels with dedicated CNV analysis are cost-effective and have good detection rates; recommended as routine approach for most inherited arrhythmia presentations. (sources/arrhythmia-genetics-mgenetik-2025 — high)
- CNV/SV analysis is becoming routine; deep intronic variants, balanced translocations, inversions require WGS. (sources/arrhythmia-genetics-mgenetik-2025 — high)
Role in Incidental Variant Evaluation (AHA 2023)
- Evaluation and clinical follow-up of incidentally identified CVD gene variants is best done at, or in close consultation with, a multidisciplinary centre specialising in cardiovascular genetics (sources/incident-gene-aha-2023 — high)
- Core workflow: re-evaluate the laboratory's pathogenicity assertion using ClinVar, ClinGen, and ACMG guidelines; conduct comprehensive clinical evaluation for the implicated disease; apply the Bayesian framework to arrive at posttest probability; coordinate longitudinal follow-up every 1–3 years
- Genetic cardiologists, cardiovascular genetic counsellors, and geneticists must take a more active and consistent role in variant review to ensure the most accurate information is applied to patient care over time (sources/incident-gene-aha-2023 — high)
- Incidental variant evaluation cannot be delegated solely to primary care; specialty centre interface is essential, including telehealth models for scaling (sources/incident-gene-aha-2023 — high)
- See concepts/Incidental-Cardiovascular-Variants for the full clinical framework
Education and Certification
- Cardiogenetics has not historically been part of traditional cardiology, pediatric cardiology, or genetics fellowship training.
- Programs filling the gap include EHRA educational courses, EP fellowships, and ERN Reference Network Guard-Heart webinars. (sources/arrhythmia-genetics-mgenetik-2025 — high)
Contradictions / Open Questions
- Access inequality: Cardiogenetic centres are currently limited to leading academic institutions, creating geographic and payer-based inequity in access to genotype-guided arrhythmia care. The recommendation for genetic testing is Class I for many arrhythmia syndromes (LQTS, BrS, CPVT, SQTS), yet clinical infrastructure to deliver this testing universally does not yet exist. (sources/arrhythmia-genetics-mgenetik-2025)
- VUS burden from larger panels: Expanding to WES or large gene panels increases VUS findings without improving variant detection rate for confirmed diagnoses, creating clinical workload for expert review and uncertainty for patients — an ongoing challenge without a standardized management pathway. (sources/arrhythmia-genetics-mgenetik-2025)
Connections
- Related to concepts/Cascade-Family-Screening
- Related to concepts/Variant-Reclassification
- Related to entities/Long-QT-Syndrome
- Related to entities/Brugada-Syndrome
- Related to entities/CPVT
- Related to entities/Short-QT-Syndrome
- Related to concepts/iPSC-Derived-Cardiomyocytes
- Related to concepts/Incidental-Cardiovascular-Variants
- Related to sources/incident-gene-aha-2023